ストックスクリーナーアプリを入手
0.9841
0.42%
0.0041
アフターアワーズ：
.99
0.0059
+0.60%
Opus Genetics Inc (IRD) 最新ニュース
Opus Genetics Inc CEO George Magrath Purchases 100,000 Shares - GuruFocus.com
FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World
Opus Genetics Inc (IRD) Quarterly 10-Q Report - Quartzy
Opus Genetics reinstated with a Buy at H.C. Wainwright - Yahoo Finance
IRD stock touches 52-week low at $1.07 amid market challenges - Investing.com India
Opus Genetics (IRD) Stock Chart and Price History 2024 - MarketBeat
Wainwright sets stock target on Opus Genetics, cites 2025 catalysts By Investing.com - Investing.com UK
Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Opus Genetics Reports $7.5 Million Net Loss in Third Quarter - Vision Monday
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard
Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com
North Carolina gains public company with merger - The Business Journals
Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter
Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday
Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com
Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance
Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL
Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo Finance
Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire
AAO 2024: Epimacular membranes and metamorphopsia - Ophthalmology Times
Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors - The Manila Times
Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini
Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com
Ocuphire Pharma acquires Opus Genetics - Seeking Alpha
Derrick D. Rowe - Wilson Sonsini
News in Cell and Gene Therapy for Rare Cancer Day 2024 - CGTLive™
EyeCon 2024: Taking a multidisciplinary approach to diabetic eye care - Optometry Times
Boehringer Ingelheim to advance SZN-413 for retinal diseases - BioWorld Online
EURETINA 2024: Aleksandra Rachitskaya, MD, FASRS, and the Vit-Buckle Society come to Barcelona - Ophthalmology Times Europe
VEW 2024: Touring the retina with Dr. Steven Ferrucci - Optometry Times
Study: 100x improvement in sight detected after gene therapy trial - Modern Retina
Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy - Ophthalmology Times
This Week in Ophthalmology: Week of August 18, 2024 - Ophthalmology Times
Opus Genetics Receives Rare Pediatric Disease Designation From the FDA for Ocular Gene Therapy - Vision Monday
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
William Chou, MD, on Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations - CGTLive™
PHOTON Results and Their Relation to DME Patients in Your Practice - Ophthalmology Times Europe
ASRS 2024: A novel approach to myopic traction maculopathy - Ophthalmology Times Europe
ASRS 2024: Diabetic retinopathy lesions and assessing disease severity over time - Ophthalmology Times Europe
Layoff Tracker: 23andMe to Lay Off 40% of Employees - BioSpace
Vertex’s Diabetes Cell Therapy on Track to Meet Endpoint of Eliminating Severe Hypoglycemic Events - CGTLive™
Gene Therapy Improves Body Composition in Mice Models of Obesity Alone and After Semaglutide Withdrawal - CGTLive™
Salvador Rico, MD, PhD, on Developing Gene Regulation Therapy for Dravet Syndrome - CGTLive™
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 19, 2024 - CGTLive™
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility - CGTLive™
Around the Helix: Cell and Gene Therapy Company Updates – June 12, 2024 - CGTLive™
Department of HealthAbu Dhabi and Opus Genetics Announce Collaboration to Advance Ground-Breaking Gene Therapy Research for Inherited Retinal Diseases - PR Newswire
Intellia’s Phase 3 Clinical Trial for CRISPR-Based Gene Therapy Enrolls First Patient - CGTLive™
Coave Therapeutics showcases its Aligater platform for generating conjugated AAV vectors to deliver ocular gene therapy through suprachoroidal route - Modern Retina
Prevent Blindness declares May Inherited Retinal Disease Genetic Testing Awareness Month to expand knowledge on IRD testing - Modern Retina
Amit Soni, MD, on Treating the First Patient With Hemophilia A Gene Therapy in the Real-World Setting - CGTLive™
Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight - PR Newswire
Verve Moves on to Second Gen Cardiovascular CRISPR Therapy After Adverse Events - CGTLive™
Vision loss's role in accessibility advocacy with Rebecca Alexander - Optometry Times
Nanoscope Therapeutics lead candidate MCO-010 meets endpoints in RESTORE trial for retinitis pigmentosa - Modern Retina
John A. Charlson, MD, on Afami-Cel’s Upcoming Review for Synovial Sarcoma - CGTLive™
First Patient Treated in Trial for NSCLC T-cell Therapy Deltacel Shows Evidence of Tumor Reduction - CGTLive™
Frederick “Eric” Arnold, PhD, on Investigating Alternative Polyadenylation in ALS Models - CGTLive™
Bio-Rad launches vericheck ddPCR replication competent lentivirus and replication competent AAV kits for cell and gene therapy production - News-Medical.Net
Alexis Kuhn, PharmD, BCOP, on Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective - CGTLive™
N. Nora Bennani, MD, on Investigating VSV Therapy in Patients With R/R Multiple Myeloma, T-Cell Lymphoma - CGTLive™
symbol__ Stock Quote Price and Forecast - CNN
EyePod: Modifier Gene Therapy: What is it? - Ophthalmology Times
David Shyr, MD, on Surprising Findings With CRISPR Cell Therapy Nula-Cel in Sickle Cell Disease - CGTLive™
0.93%
3.55%
大文字化:
|
ボリューム (24 時間):